Dako and Cell Signaling Technology partner in companion diagnostics

Tuesday, 13 January, 2015

Antibody provider Cell Signaling Technology (CST) has entered into a strategic partnership to supply antibodies for use in Dako companion diagnostics products. Dako, an Agilent Technologies company, is a worldwide provider of cancer diagnostics.

Dako has a record of successful long-term partnerships with companies such as Pfizer, AstraZeneca, Bristol-Myers Squibb, Merck & Co, Amgen and Eli Lilly. Jacob Thaysen, president of Agilent’s Diagnostics and Genomics Group, said the company is now “pleased to work with CST in the development of high-quality, cutting-edge companion diagnostic products that will be an important tool in the diagnosis and treatment of cancer”.

The market for companion diagnostics is steadily growing, as personalised medicine may improve patient care and assist in managing healthcare costs by targeting treatments to individuals more likely to benefit from specific therapies. According to CST CEO Michael J Comb, “Companion diagnostic products have great potential to improve the way we diagnose and treat patients with cancer.

“We believe this partnership will allow our products to contribute to the advancement of personalised medicine,” Comb added.


Related News

Partnership provides tools for cell-based meat research

Reagent company Kerafast has announced an agreement with The Good Food Institute, an organisation...

Better antibody validation required, study says

A new study points to the need for better antibody validation and outlines a process that other...

Edible antibodies to treat gastrointestinal disorders

Scientists have developed a new antibody technology that combines the advantages of...

  • All content Copyright © 2020 Westwick-Farrow Pty Ltd